Form 6-K Forward Pharma A/S For: Dec 06
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
December 6, 2022
Commission File Number: 001-36686
Forward Pharma A/S
Østergade 24A, 1st Floor
1100 Copenhagen K, Denmark
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Item 1. Other Items
On December 6, 2022, Forward Pharma A/S issued a press release regarding the decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 petition for review, a copy of which is attached hereto as Exhibit 99.1.
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press Release dated December 6, 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| FORWARD PHARMA A/S | ||
| Date: December 6, 2022 | By: | /s/ Claus Bo Svendsen |
| Name: Claus Bo Svendsen | ||
| Title: Chief Executive Officer | ||
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sodexo announces solid H1 Fiscal 2024 results
- Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
- Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
